Related Experiment Video
Updated: Apr 29, 2026
10:39
3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
Published on: June 2, 2014
19.1K
Clopidogrel as prophylactic treatment for migraine: a pilot randomised, controlled study
John B Chambers1, Paul T Seed2, Leone Ridsdale3
1Cardiothoracic Centre, St Thomas Hospital, UK john.chambers@gstt.nhs.uk.
Cephalalgia : an International Journal of Headache
|May 20, 2014
Summary
This pilot study found no significant difference in migraine prevention between clopidogrel and placebo. Further multicenter trials are suggested to explore clopidogrel
Area of Science:
- Neurology
- Pharmacology
Background:
- Anecdotal evidence suggests clopidogrel may prevent migraine attacks.
- A pilot randomized trial was conducted to investigate this potential therapeutic effect.
Purpose of the Study:
- To evaluate the efficacy of clopidogrel in preventing migraine attacks.
- To assess the impact of clopidogrel on headache frequency and severity.
Main Methods:
- A randomized, placebo-controlled trial involving migraineurs with 4-15 headache days/month.
- Participants received either clopidogrel 75 mg or placebo daily for three months.
- Headache frequency and severity were monitored using daily headache diaries.
Main Results:
- No statistically significant difference in headache days between clopidogrel and placebo groups (1.9 vs 1.6 days reduction).
- A slight increase in headache severity was observed with clopidogrel, while placebo showed a decrease (treatment effect 0.7 points).
- Treatment effects were consistent regardless of migraine with aura, patent foramen ovale, or atrial septal aneurysm.
Conclusions:
- Current evidence is inconclusive regarding clopidogrel's efficacy for migraine prevention.
- A larger, multicenter trial is feasible and recommended for further investigation.
- Primary care recruitment is a viable strategy for future migraine research.
